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Introduction
Gout is a clinical disorder caused by deposition of urate
crystals in a joint leading to acute inﬂammatory res-
ponse with acute pain. In severe and longstanding gout,
the crystals accumulate in soft tissues such as cartilage,
subcutaneous tissue or even veins leading to the
development of tophi responsible for very large deposit
formations and disability. Most cases of gout present
with the sudden onset of severe acute arthritis in a
peripheral joint in the leg.
Urate oxidase, or uricase (EC 1.7.3.3), is a per-
oxisomal liver enzyme that catalyses the enzymatic
oxidation of uric acid into the more water-soluble
allantoin (Figure 1). Urate oxidase is an endogenous
enzyme found in most mammals but not in humans.
During primate evolution, the inactivation of the
hominoid urate oxidase gene was caused by indepen-
dent nonsense or frameshift mutations and has taken
a two-step deterioration process, ﬁrst in the promotor
and second in the coding region [1]. Two nonsense
mutations were found in the human urate oxidase gene,
which conﬁrms, at the molecular level, that the urate
oxidase gene in humans is non-functional [2–3].
Because uric acid is a powerful scavenger of free
radicals, it has been proposed that uric acid plays an
important role in protection hominoids from oxidative
damage and the prolonged live span [1,4].
Urate oxidase is used in humans for the control
of increased serum uric acid in patients with acute
tumour lysis syndrome after receiving chemotherapy.
Rasburicase (SR 29142), a recombinant urate oxidase
expressed in Saccharomyces cerevisiae, has been
demonstrated to be superior to allopurinol in the
control of uric acid in a randomized trial of paediatric
and adult patients at risk of acute tumour lysis
syndrome [5,6]. However, only few case reports address
the potential role of urate oxidase for treatment of
severe tophaceous gout. A French group treated three
heart transplant patients with uncontrollable gout with
non-recombinant urate oxidase and observed shrinking
of tophi and improved mobility of the ﬁngers in all
three patients [7]. Phillips and co-workers used rasburi-
case for treatment of severe tophaceous gout refractory
to high-dose allopurinol in a patient with end-stage
renal disease and observed a regression of gout tophi
[8]. The treatment was well tolerated in all reported
patients and produced no adverse effects.
We analysed efﬁcacy and safety of rasburicase in the
long-term control of hyperuricaemia in an adult kidney
transplant patient with severe tophaceous gout.
Case report
A 33-year-old female patient suffered from severe
tophaceous gout. Kidney transplantation was per-
formed 8 years ago for end-stage renal disease caused
by bilateral vesico-ureteral reﬂux disease in childhood.
Renal function remained stable (creatinine clearance
30ml/min). Hyperuricemia was present since the time
of end stage renal failure with eight to 12 gout attacks
per year treated with steroids and colchicine.
Allopurinol was not given because of allopurinol
allergy. Anorectic behaviour and therapy with cyclos-
porine together with loop diuretics contributed to
hyperuricemia. During the last 6 years, severe tophac-
eous gout developed with large deposits in all ﬁngers of
both hands as well as in the feet. The tophi recurred
despite repetitive surgical removal and led to signiﬁcant
disability due to previous sensory loss (Figure 2).
A therapy with the recombinant urate oxidase
rasburicase (Fasturtec, i.e. SR29142 from Sanoﬁ-
Synthelabo, Geneva, Switzerland) 0.15mg/kg body
weight i.v. every second week was started. Serum uric
acid decreased from base line levels of 850 mM to
values below 50 mM during the ﬁrst week after therapy
and increased steadily during the subsequent weeks
to levels before therapy during the ﬁrst 6 month
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treatment period. Thereafter, and for the rest of the 3
years of monthly rasburicase therapy, serum uric acid
decreased from 850 to 658 mM (mean of three values).
Following rasburicase injection, serum uric acid
decreased despite a concomitant decrease in urinary
excretion of uric acid (fractional excretion of uric acid
decrased from 8% to 3%), indicating metabolism of
uric acid unrelated to renal elimination. In the presence
of decreased fractional excretion of uric acid, one
potential mechanism for the decrease in serum uric acid
is the elimination of uric acid metabolites by transport
mechanisms similar to that of uric acid. Proteinuria of
0.20–0.35 g/24 h remained stable during the 3 years of
therapy. Rasburicase therapy was well tolerated and
produced no adverse effects besides occasional episodes
of inﬂammation observed during the ﬁrst 2 months
of therapy. These episodes of mild inﬂammation of
multiple joints (symmetrically ﬁngers, knees and feet)
disappeared when the dose was lowered and the
interval between two doses was prolonged. With
0.15mg/kg body weight of rasburicase every fourth
week, the patient remained without side effects during
3 years of follow-up. No gout attack occurred since
the start of rasburicase therapy. The size of the tophi
decreased substantially and the patient’s functional
capacity improved dramatically (Figure 3).
Discussion
Urate oxidase is an enzyme that catalyses the conver-
sion of uric acid into allantoin, which is 10 times more
soluble than uric acid and more readily eliminated by
the kidney. Humans and certain primates lack this
enzyme. Administered intravenously, urate oxidase is a
potent and fast-acting urate-lowering drug used for the
prevention of acute urate nephropathy during tumour
lysis following cytolytic therapy. As demonstrated in
this patient, to the best of our knowledge the ﬁrst renal
transplant patient, urate oxidase can be used to reduce
serum uric acid to a degree that will facilitate the
resorption of tophi and improve functional capacity in
patients with severe gout who have allopurinol intol-
erance to.
Rasburicase, a recombinant urate oxidase, which is
an urolytic agent, and has been developed for the
prevention and treatment of chemotherapy-induced
hyperuricemia and acute renal failure induced by
tumour lysis [6,9]. In this indication, the recommended
dosage is 0.20mg/kg per day for 5–7 days. Signiﬁcant
reductions from baseline in plasma uric acid levels were
seen in a randomized comparative trial of rasburicase
versus allopurinol in pediatric patients at high risk of
tumour lysis syndrome. The efﬁcacy and safety of
rasburicase for the prevention and treatment of hyper-
uricaemia during induction chemotherapy of aggressive
non-Hodgkin’s lymphoma has been demonstrated in
several clinical studies such as the recent GRAAL1
(Groupe d’Etude des Lymphomes de l’Adulte Trial on
Rasburicase Activity in Adult Lymphoma) study [5].
Rasburicase was well tolerated in clinical trials, with
skin rashes reported in <2% of patients [6]. Therefore,
short-term administration of rasburicase can be
regarded as well tolerated with very few side effects.
However, to date no experience of long-term therapy
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Fig. 1. Purin pathway. Allopurinol blocks the conversion of
xanthine to uric acid. The urate oxidase rasburicase catalyses the
oxidation of uric acid to allantoin, a highly water-soluble metabolite
readily excreted by the kidney.
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Fig. 2. Left and right hand from the 33-years-old female patient with
severe gout tophi on both hands leading to pain and functional
disability.
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with rasburicase exists. In this regard, our patient
represents the ﬁrst report on a 3 year rasburicase
therapy. The very few side effects observed at the
beginning of therapy disappeared after 2 months of
treatment, and then the patient was event free for the
remaining 3 years. Two reasons may account for this:
ﬁrst, the immunosuppressive therapy with cyclosporine
A and prednisone administered concomitantly might
facilitate the excellent tolerance, and second, rasburi-
case has a high degree of purity since the structure of
the molecule is maintained by a speciﬁc puriﬁcation
process [10].
The dramatic regression of gout tophi in the ﬁnger
tips indicates that a substantial amount of uric acid
tissue deposits can be mobilized by long-term rasburi-
case therapy.
Treatment of severe gout remains a challenge in
medicine. Today, therapeutic options to decrease serum
uric acid consist of diet and uricostatic agents like
allopurinol [11]. Drugs known to increase serum uric
acid like diuretics and cyclosporine A usually cannot be
avoided as in the present case. Benzbromarone, an
uricosuric drug, is not in use any more because its
association with fulminant liver failure. Therefore,
urate oxidase agents might open new therapeutic
possibilities in patients with severe uncontrolled gout.
Furthermore, allopurinol allergy, albeit rare, represents
another interesting indication for these patients [12].
Despite the excellent tolerance for 3 years of the
patient described above, allergic reactions remain a
possible threat that need to be addressed in further
studies with the urate oxidase rasburicase.
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Fig. 3. Left and right hand from the 33-year-old female patient after
12 months of therapy with the urate oxidase rasburicase.
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